Table 2.
Clinical manifestations of the patients diagnosed with COVID-19 in different data sets. P values were estimated using the Student 2-tailed t test or the Mann-Whitney U test for continuous variables and the Pearson chi-square test or Fisher exact test for categorical variables.
| Clinical manifestations | Total (n=1206) | Boramae Medical Center (n=739) | Korean Imaging Cohort of COVID-19 (n=467) | P value | |
| Symptoms, n (%) | |||||
|
|
Cough | 639 (53) | 417 (56.4) | 222 (47.5) | .003 |
|
|
Fever | 624 (51.7) | 376 (50.9) | 248 (53.1) | .49 |
|
|
Dyspnea | 213 (17.7) | 128 (17.3) | 85 (18.2) | .79 |
| Laboratory tests | |||||
|
|
White blood cells (cells/µL), mean (SD) | 5024 (1941) | 4984 (1932) | 6007 (1926) | .005 |
|
|
Lymphocytes (%), mean (SD) | 29.4 (10.9) | 29.5 (11.4) | 29.2 (9.0) | .70 |
|
|
C-reactive protein (mg/dL), median (IQR) | 0.42 (0.12 to 1.83) | 0.65 (0.17 to 3.14) | 0.30 (0.10 to 0.38) | <.001 |
|
|
Procalcitonin (ng/mL), median (IQR) | 0.03 (0.01 to –0.04) | 0.03 (0.02 to –0.05) | 0.02 (0.00 to –0.04) | .02 |
| Treatment, n (%) | |||||
|
|
Remdesivir | 70 (5.8) | 58 (7.8) | 12 (2.6) | <.001 |
|
|
Corticosteroid | 115 (9.5) | 74 (10) | 41 (8.8) | .55 |
| Length of stay (days), median (IQR) | 15 (11 to 24) | 13 (10 to 19) | 22 (15 to 30) | <.001 | |
| Length of stay ≤2 weeks, n (%) | 562 (46.6) | 451 (61) | 111 (23.8) | <.001 | |
| Oxygen supplementation, n (%) | 222 (18.4) | 160 (21.7) | 62 (13.3) | <.001 | |
| High-flow nasal cannula, n (%) | 65 (5.4) | 55 (7.4) | 10 (2.1) | <.001 | |
| Mechanical ventilator, n (%) | 60 (5) | 31 (4.2) | 29 (6.2) | .15 | |
| Extracorporeal membrane oxygenator, n (%) | 18 (1.5) | 7 (0.9) | 11 (2.4) | .08 | |